EANM procedure guidelines for 32P therapy.
D005060:Europe; D006801:Humans; D009196:Myeloproliferative Disorders / Q000175:diagnosis / Q000532:radiotherapy; D009683:Nuclear Medicine / Q000592:standards; D018579:Patient Selection; D010761:Phosphorus Radioisotopes / Q000627:therapeutic use*; D011087:Polycythemia Vera / Q000175:diagnosis / Q000532:radiotherapy*; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D011878:Radiotherapy / Q000379:methods / Q000592:standards*; D012955:Societies, Medical / Q000592:standards; D013920:Thrombocythemia, Essential / Q000175:diagnosis / Q000532:radiotherapy*; D017211:Treatment Failure; D016896:Treatment Outcome
D010761:Phosphorus Radioisotopes; D019275:Radiopharmaceuticals